We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Gives Repros the Go-Ahead for Low-Dose Proellex Study
FDA Gives Repros the Go-Ahead for Low-Dose Proellex Study
June 23, 2010
The FDA has allowed Repros Therapeutics to run a single, low-dose study of its uterine fibroid and endometriosis drug Proellex under a partial clinical hold.